Kumsal Bayazit appointed Chief Executive Officer of Elsevier
Amsterdam | January 28, 2019
Elsevier, the information analytics business specializing in science and health, today announced Kumsal Bayazit has been appointed Chief Executive Officer effective February 15, 2019.
Bayazit has worked at RELX Group, Elsevier’s parent company, since 2004. She started her career at Legal and Risk & Business Analytics, where she held a number of senior strategy and operational roles. In 2012, she was appointed Chief Strategy Officer of RELX Group, as well as chair of the company’s Chief Technology Officers’ Forum, formed to foster a strategic acceleration into an increasingly data-driven business focused on analytics and decision tools. For the past three years, she has been the Regional President for Europe, Middle East and Africa at RELX Group’s exhibitions business. Prior to joining RELX Group, Bayazit worked at Bain & Company in the US, South Africa and Australia. She holds an MBA from Harvard Business School and is a graduate of the University of California at Berkeley.
Bayazit replaces Ron Mobed who, after seven years as Elsevier’s Chief Executive Officer, has decided to retire. Mobed joined Elsevier in 2011 and became Chief Executive in 2012. He will support his successor during the transition, providing counsel and advice until June. Youngsuk (YS) Chi will remain Chairman of Elsevier.
About RELX Group
RELX Group is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs about 30,000 people of whom almost half are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. The market capitalisation is approximately £32bn, €37bn, $42bn. www.relx.com(opens in new tab/window)
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses.
Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, medical education, and nursing education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet(opens in new tab/window) and Cell(opens in new tab/window); 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation(opens in new tab/window) and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX(opens in new tab/window), a global provider of information-based analytics and decision tools for professional and business customers.